Published in Oncoimmunology on July 01, 2012
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A (2013) 2.29
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14
Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. Curr Opin HIV AIDS (2016) 0.86
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med (2014) 0.85
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. Oncoimmunology (2016) 0.78
Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight (2016) 0.78
Tumor immunology: multidisciplinary science driving basic and clinical advances. Cancer Immunol Res (2013) 0.78
Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. Blood (2016) 0.76
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science (2007) 7.64
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol (2002) 4.17
Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol (2009) 3.19
Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (2001) 2.95
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med (2001) 1.88
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 4.13
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol (2006) 2.36
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology (2009) 2.22
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res (2009) 1.63
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology (2012) 1.47
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res (2009) 1.39
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A (2013) 1.35
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res (2004) 1.35
Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother (2011) 1.34
Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr (2013) 1.29
Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 1.24
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) (2009) 1.23
Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res (2011) 1.22
Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol (2008) 1.20
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease. J Immunol (2010) 1.14
Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol (2009) 1.12
Targeting regulatory T cells. Target Oncol (2012) 1.10
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology (2012) 1.08
Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood (2007) 1.01
Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst (2013) 1.01
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol (2008) 0.97
Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. Infect Immun (2002) 0.97
Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol (2011) 0.96
TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice. PLoS One (2013) 0.93
Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev Immunol (2011) 0.93
Regulatory T cells in human ovarian cancer. J Oncol (2012) 0.90
Retracted Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol (2013) 0.90
Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med (2011) 0.86
Clinicopathologic Features of Gastric Schwannoma: 8-Year Experience at a Single Institution in China. Medicine (Baltimore) (2015) 0.84
HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochem Biophys Res Commun (2013) 0.84
The chemokine SDF-1/CXCL12 contributes to T lymphocyte recruitment in human pre-ovulatory follicles and coordinates with lymphocytes to increase granulosa cell survival and embryo quality. Am J Reprod Immunol (2005) 0.83
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother (2007) 0.83
Blocking HDACs boosts regulatory T cells. Nat Med (2007) 0.83
Modeling dynamic changes in type 1 diabetes progression: quantifying beta-cell variation after the appearance of islet-specific autoimmune responses. Math Biosci Eng (2009) 0.82
The B7 homologues and their receptors in hematologic malignancies. Eur J Haematol (2012) 0.82
T cells and costimulation in cancer. Cancer J (2013) 0.81
Role of IL-17 and TGF-β in peritoneal adhesion formation after surgical trauma. Wound Repair Regen (2014) 0.80
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 0.80
Inhibitory B7 family members in human ovarian carcinoma. Adv Exp Med Biol (2008) 0.79
Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma. Virology (2003) 0.79
Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest (2012) 0.79
T lymphocytes to IDO+ cells: check. Blood (2011) 0.78
Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products. Eur J Haematol (2002) 0.76
Nine lives for TH9s? Nat Med (2012) 0.76
Influence of bariatric surgery on the expression of nesfatin-1 in rats with type 2 diabetes mellitus. Curr Pharm Des (2015) 0.75
Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discov Med (2005) 0.75